EnLyte to Be Presented at the Medical Academy of Pediatric Special Needs Conference in Orlando, September 11-13

Orlando, Florida (PRWEB) September 11, 2014

JayMac Pharmaceuticals, LLC, Makers of EnLyte with Delta Folate, are participating in the Medical Academy of Pediatric Special Needs (MAPS) conference set to take place in Orlando September 11-13. MAPS brings together medical providers from around the nation for an in-depth curriculum aimed at educating on the treatment of children with autism spectrum disorder and other special needs conditions.

Families of children with these needs are increasingly seeking alternative treatment options. In fact, in a new study published in the Journal of Developmental and Behavioral Pediatrics, 40% of families with children who have autism or other developmental disorders said they use alternative medicine to treat their children, along with conventional therapies.

EnLyte with Delta Folate is an advanced generation prescription folate therapy designed to address common genetic polymorphisms such as the MTHFR defect, and to lower elevated homocysteine-two factors common in ASD. According to Dr. Lawrence Ginsberg, MD, of Red Oak Psychiatry, the implications of high homocysteine in ASD are decreased neurological functioning and neural degeneration during fetal development.

Factors like diet restrictions, absorption issues, and genetic factors-most notably the MTHFR defect-are unique and significant to Autism, being major players in decreasing the body’s ability to absorb B vitamins. Dr. Ginsberg has found an incidence of about 90% of the MTHFR defect in his practice in patients with autism spectrum disorders-meaning as much as a 70% reduction in their ability to use certain B vitamins.

The Autism Society has been in favor of supplements for years, Dr. Ginsberg states, and he finds many parents welcome an alternative to antipsychotics. Shelley Hendrix, parent of an 18 year old Autistic son: “It’s been my experience over the last 16 years that I’ve been in the Autism community that parents are experimenting with alternative treatments for their children. It’s nice to finally find a nutritional supplement regulated by the FDA that provides a uniform dose that avoids the common allergens such as gluten and dairy. It is also great to have a product like this that is prescribed by a physician and covered under most insurance and Medicaid. For families of children with autism who have been paying thousands of dollars out of pocket to provide nutritional supplements for their kids, this is very welcome news.”

About EnLyte
EnLyte Is the first and only prescription folate therapy containing L-Methylfolate Magnesium, Folinic Acid, and Folic Acid, and all the necessary B-vitamin metabolites, in optimal doses, to completely address the remethylation and transsulfuration cycles, address genetic polymorphisms, and reduce high homocysteine. It is gluten free, casein free, dye free, and preservative free.

About JayMac
JayMac Pharmaceuticals, LLC is a Sunset, Louisiana-based pharmaceutical company gaining interest with the introduction of EnLyte into the psychotropic and psychiatric market.

Learn more at http://www.EnLyteRx.Com

EnLyteRx Expert Video: Depression Linked To Folate Deficiency

Sunset, LA. Jan. 23, 2015 (GLOBE NEWSWIRE) — JayMac Pharmaceuticals, makers of EnLyte, have released an expert video on a natural option for treating depression that may be linked to folate deficiency. Andrew Farah, MD, Chief of Psychiatry of UNC Healthcare, and an expert in the use of B vitamins in mental health, hosts this first in a series of videos:

Folate deficiency is related to many conditions including depression, fibromyalgia, chronic fatigue syndrome, ADD/ADHD, and migraine. Click here to read more about folate deficiency. Depression, in particular, is strongly linked to folate deficiency, as folate is critical in producing the chemicals-neurotransmitters-that regulate mood: serotonin, norepinephrine, and dopamine. Research suggests that there is about a 67% increase in depression in people who are folate-deficient.

However, there is a common enzyme defect about 60% of the general U.S. population has, the MTHFR enzyme polymorphism, that makes it harder for the body to break down folic acid from diet or supplements into the form the body can use to make neurotransmitters. Standard antidepressants such as SSRIs and SNRIs come with common side effects like weight gain and sexual dysfunction. About 60% of people don’t finish their recommended course of therapy due to side effects, increasing the need for natural but effective alternatives. Folate therapy is recommended by the American Psychiatric Association and the APA CAM Guidelines as a safe and effective option to be added to existing antidepressant therapy, and EnLyte has a strong following in the medical community.

EnLyte is an FDA-regulated, prescription folate therapy containing L-Methylfolate magnesium, folinic acid, and folacin, plus all of the brain-ready B vitamins: B1, B2, B3, B6, B12, and betaine, zinc, magnesium, vitamin C, and PS Gold omega 3’s. It is gluten free and artificial dye free, and safe for use in pregnancy and lactation.

EnLyte may be used alone or added to certain antidepressants, and is dosed once a day. It is paid for by many insurance plans with an average patient copay of $44, many state Medicaid plans, Tricare for $17, and $58 per month through mail order.

To learn more, visit www.EnLyteRx.Com, or contact EnLyte Customer Care at 985-788-7755.

Angela Hall
JayMac Pharmaceuticals, LLC

– See more at:

eSYNCS | Advertising Agency